Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$148.44K$148.44Kderived+252.3% vs Q4 2018 Net Income-$5.66M-$5.66MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$101,268+197.3% Operating Incomederived-$729,997N/M Operating Cash Flowderived-$308,381N/M Free Cash Flowderived-$308,381N/M Margins · derivedGross margin68.2%−12.6 pt vs Q4 2018
Operating margin-491.8%+1957.8 pt vs Q4 2018
Net margin-3815.9%
ended Dec 31, 2019 · filed May 4, 2020 · 125 d after period end